CHENNAI, India — Authorities have apprehended a 75-year-old pharmaceutical owner over allegations tied to a deadly cough syrup linked to several child fatalities across multiple states. Ranganathan, the proprietor of Sresan Pharma, was taken into custody by a Special Investigation Team from Madhya Pradesh in conjunction with the Chennai City Police.
Ranganathan was arrested at his home in Kodambakkam and later transported to the Sunguvarchatram police station in Kancheepuram district for initial questioning. The arrest stems from the production of a cough syrup named ‘Coldrif,’ which reportedly contained diethylene glycol (DEG), a hazardous substance implicated in the tragic deaths of young consumers.
The Madhya Pradesh police have embarked on a comprehensive investigation into the matter. A transit warrant is currently being processed to enable Ranganathan’s transfer back to Madhya Pradesh for further questioning under custodial supervision.
In the wake of Ranganathan’s arrest, investigators conducted a thorough examination of Sresan Pharma’s manufacturing site in Sunguvarchatram, a facility operating out of a 4,500-square-foot rented space. Following this inspection, the local Drugs Control Department took immediate action by sealing the facility due to numerous violations of pharmaceutical manufacturing regulations.
Sources familiar with the investigation indicated that the pharmacy allegedly fell short in sourcing pharmaceutical-grade propylene glycol, a crucial component in cough syrup formulation. Instead, the company reportedly used inferior materials, contaminated with DEG. Subsequent tests on samples collected from the site confirmed the presence of this toxic substance.
Officials have directed their focus to understanding the broader supply chain and compliance failures that led to this hazardous situation. There are growing concerns about the safety regulations governing pharmaceutical production, and this case has prompted discussions among authorities about strengthening oversight to prevent future occurrences.
As the investigation unfolds, authorities emphasize the need for heightened scrutiny of manufacturing practices within the pharmaceutical industry. The tragic implications of this case serve as a sobering reminder of the potential dangers that can arise from neglecting safety standards. Following legal procedures, it is anticipated that Ranganathan will be transferred to MadhyaPradesh soon, where the ongoing investigation continues to shed light on this disturbing incident.
Local residents and parents, alarmed by the news, have expressed their outrage and concerns over the safety of medicinal products. Community leaders are calling for stricter regulations and increased accountability among pharmaceutical manufacturers to safeguard public health, particularly for children who are the most vulnerable.
This incident raises troubling questions about the integrity of the supply chain in the pharmaceutical industry and the efficacy of current regulatory frameworks. As authorities delve deeper into the investigation, the hope is that it will lead to meaningful changes that prevent similar tragedies in the future.
In a broader context, this event highlights the critical importance of maintaining quality control in drug manufacturing, as lapses not only endanger lives but also undermine public trust in medical products. The fallout from this case will likely prompt a nationwide discussion on improving pharmaceutical safety protocols and enforcing compliance with stringent standards.